First-in-Human, Phase I Study of PCA062 in Solid Tumors—Letter

医学 癌症研究 腺癌 癌症 内科学
作者
Bernadette de Rauglaudre,Pascal Finetti,David Jérémie Birnbaum,Marc Lopez,François Bertucci,Émilie Mamessier
出处
期刊:Molecular Cancer Therapeutics [American Association for Cancer Research]
卷期号:21 (11): 1742-1743
标识
DOI:10.1158/1535-7163.mct-22-0240
摘要

In a recent issue, Duca and colleagues reported the results of a first-in-human phase I study of PCA062, an antibody–drug conjugate (ADC) targeting P-cadherin (CDH3), in patients with CDH3-positive solid tumors (1). The clinical development of PCA062 was, however, terminated due to its limited antitumor activity at MTD. Here, we would like to point out that the therapeutic development of a third-generation CDH3-ADC should still be considered as an interesting strategy for pancreatic adenocarcinoma (PAAD).PAAD is one of the most pejorative cancers with few treatment options. The most represented tumors in the Duca and colleagues’ study were esophagus and head and neck squamous cell carcinomas (respectively, ESCC n = 9, and HNSCC n = 6); the detailed information on the tumor type was not available for the other 31 patients enrolled, impeding to identify the number of patients with PAAD (at least one). Although inferior to expression in the most represented tumors in Duca and colleagues’ study, PAAD samples expressed moderate levels of CDH3, with very elevated fold-changes when compared with normal tissues (Fig. 1A). In our database (1,090 PAAD tumors), we confirmed the significant upregulation of CDH3 in primary tumors and metastases (Fig. 1B), and CDH3 overexpression was an independent poor-prognosis factor for survival (Fig. 1C). The negative Duca and colleagues’ results, notably in tumors with high CDH3 expression (ESCC, HNSCC), did not suggest that CDH3 expression could be a predictive marker for response to CDH3-ADC. A low ABCC1/SLC46A3 gene expression ratio was associated with response to this CDH3-ADC in preclinical models (2); interestingly, we found that PAAD displayed the smallest ratio when compared with 18 other carcinoma types, including HNSCC and ESCC (that displayed high and unfavorable ratios; Fig. 1D), suggesting higher potential vulnerability of PAAD.Furthermore, PAAD should also benefit from a third-generation ADC. Indeed, PCA062 is a second-generation ADC, that is, with the anti-CDH3 antibody being directly conjugated to a noncleavable maytansine-derived SMCC-DM1 linker-payload. Such ADCs were designed to kill tumors expressing high levels of target. A noncleavable linker limits the bystander killing effect of adjacent cancer cells and is less suitable in tumors with heterogeneous or moderate target expression, like CDH3 in PAAD. Finally, a DM1 payload might be less optimal than a topoisomerase-I inhibitor, as already shown in pancreatic cancer cells (3). Third-generation ADCs that associate cleavable linkers, which increase the bystander effect, and topoisomerase I inhibitors are expected to be more efficient, as exemplified by the increased efficacy of trastuzumab–deruxtecan versus Trastuzumab–DM1 in HER2+ colon and gastric cancers (4, 5).Thus, we suggest that a third-generation CDH3-ADC might be better suited in solid tumors such as PAAD and deserves further evaluation.M. Lopez is a cofounder and shareholder of Emergence Therapeutics. No disclosures were reported by the other authors.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
骑驴追火箭完成签到,获得积分10
1秒前
baomingqiu完成签到 ,获得积分10
1秒前
乐观寻雪完成签到 ,获得积分10
3秒前
量子星尘发布了新的文献求助10
4秒前
复杂勒完成签到,获得积分10
4秒前
5秒前
bird完成签到,获得积分10
6秒前
AaronDP发布了新的文献求助50
7秒前
terryok完成签到,获得积分10
8秒前
Cll完成签到 ,获得积分10
8秒前
聪明的宛菡完成签到,获得积分10
9秒前
CNYDNZB完成签到 ,获得积分10
9秒前
xxj完成签到 ,获得积分10
9秒前
芊芊完成签到 ,获得积分10
10秒前
yar应助bluesky采纳,获得10
10秒前
海人完成签到 ,获得积分10
11秒前
SY15732023811完成签到 ,获得积分10
13秒前
李建勋完成签到,获得积分10
13秒前
科研通AI2S应助一路芬芳采纳,获得10
13秒前
黄花完成签到 ,获得积分10
14秒前
刘珍荣完成签到,获得积分10
15秒前
15秒前
紫金之巅完成签到 ,获得积分10
15秒前
Gang完成签到,获得积分10
16秒前
17秒前
17秒前
18秒前
CYYDNDB完成签到 ,获得积分10
18秒前
粿粿一定行完成签到 ,获得积分10
19秒前
20秒前
战战完成签到,获得积分10
21秒前
xlk2222完成签到,获得积分10
24秒前
笨笨以莲完成签到,获得积分10
24秒前
YHX完成签到,获得积分10
25秒前
沐沐心完成签到 ,获得积分10
26秒前
26秒前
27秒前
哭泣笑柳发布了新的文献求助10
27秒前
轻松白桃完成签到,获得积分10
27秒前
JasVe完成签到 ,获得积分10
30秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022